GlassScriptPhysician profile
Tara J Mahan
NPI 1033496476
$4,778.86
in general payments reported to CMS, 2019-2025
36 companies · $857 in 2025
The $857 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $1,272 · 2023: $612 · 2024: $996 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $620.97 | 2021-2023 | |
| Janssen Biotech, INC. | $511.77 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Teleflex LLC | $385.57 | 2021-2024 | Urolift |
| Abbvie INC. | $371.84 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $306.57 | 2021-2025 | |
| Boston Scientific Corporation | $198.10 | 2021-2024 | Ams 700, Tactra, Ams 800 Artificial Urinary Sphincter |
| Myovant Sciences INC. | $196.14 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $188.93 | 2021-2024 | Xiaflex, Aveed, Edex |
| Urovant Sciences INC | $168.82 | 2022 | |
| Tempus Ai, INC | $164.55 | 2024-2025 | Xt Cdx |
| Immunitybio, INC. | $135.17 | 2025 | |
| Progenics Pharmaceuticals, INC. | $129.99 | 2022-2024 | |
| Tolmar Pharmaceuticals, INC. | $125.65 | 2021-2022 | |
| Pfizer INC. | $114.77 | 2022-2025 | |
| Medtronic, INC. | $113.29 | 2023 | Interstim |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $109.66 | 2024-2025 | Adstiladrin |
| Urogen Pharma, INC. | $100.69 | 2022-2025 | |
| Coloplast Corp | $98.46 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $89.64 | 2021-2025 | Keytruda |
| Sumitomo Pharma America, INC. | $87.39 | 2024-2025 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals LP | $86.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.37 | 2024 | |
| Endo USA, INC. | $50.49 | 2024-2025 | Xiaflex, Aveed, Edex |
| Tolmar, INC. | $44.86 | 2024-2025 | Eligard, Jatenzo |
| Dendreon Pharmaceuticals LLC | $42.56 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $34.17 | 2022 | |
| Blue Earth Diagnostics | $27.43 | 2025 | Posluma |
| Foundation Medicine, INC. | $27.41 | 2021-2022 | |
| Bioprotect Medical, INC. | $25.66 | 2025 | Bioprotect Balloon Implant System |
| Olympus America INC. | $24.83 | 2023 | Itind System |
| Telix Pharmaceuticals | $24.78 | 2024 | Illuccix |
| Clovis Oncology, INC. | $24.03 | 2021 | |
| Antares Pharma, INC. | $19.65 | 2022 | |
| Procept Biorobotics Corporation | $19.37 | 2023 | Aquabeam Robotic System |
| 180 Medical, INC. | $14.26 | 2024 | |
| Myriad Genetic Laboratories, INC. | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Mahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.